Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate
Status:
Recruiting
Trial end date:
2022-11-23
Target enrollment:
Participant gender:
Summary
We hypothesize that Stereotactic Body Radiotherapy Boost (SBRT) as a boost to the prostate
following whole pelvic intensity modulated radiotherapy (IMRT) can be delivered effectively
and safely in a population of men with unfavorable intermediate and high risk localized
prostate cancer.
Our primary objective is to assess the feasibility and safety of a treatment strategy
incorporating whole pelvic IMRT followed by an SBRT boost to the prostate with neoadjuvant,
concurrent, and adjuvant androgen deprivation for a total of 28 months for men with
unfavorable intermediate or high risk localized prostate cancer.